African Swine Fever roadmap:
Vaccines
Roadmap for the development of a candidate vaccine for ASF
Download ASF-Vaccine-Roadmap_Updated_Oct252
Naturally attenuated candidates
Naturally attenuated candidates
Research Question
- The development of a cross protective ASF vaccine by passage in tissue culture or a mutant low pathogenic wild type strain
Research Gaps and Challenges
-
- Lack of cross protection among different isolates
- Risk of reversion to virulence
- Candidates will need to comply with safety, quality and efficacy requirements described in the
- ASF chapter of the WOAH Manual of Vaccines and Diagnostic Tests 2025
- Ensure that the mechanism of attenuation is defined at a molecular level, and its stability is ensured through multiple gene modifications
Solution Routes
- Perform passage in tissue culture to reduce virulence
- Identify mutant low pathogenic wild strains
Dependencies
- Identify strains that give greatest cross protection
- Develop suitable cell lines for high titre propagation and licensing
State Of the Art
- Experimentally, some level of homologous protection can be achieved by inoculation of pigs with low-virulence isolates obtained by passage in tissue culture or by deletion of genes involved in virulence, as well as low virulence isolates from the field
- Challenge models have been evaluated and are available
Projects
What activities are planned or underway?
Vaccines, diagnosis and epidemiology for control and prevention of African swine fever (SE1520)
Planned Completion date 31/12/2028
Source Countries:
UK
Research, Development, Testing, and Technical Services to Advance the Technology Transfer of Veterinary Medical Countermeasures at the NBAF
Planned Completion date 21/06/2027
Source Countries:
United States